Arcutis Biotherapeutics, Inc. (ARQT)
Automate Your Wheel Strategy on ARQT
With Tiblio's Option Bot, you can configure your own wheel strategy including ARQT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARQT
- Rev/Share 2.4912
- Book/Share 1.2386
- PB 23.3652
- Debt/Equity 0.0397
- CurrentRatio 3.5003
- ROIC -0.1438
- MktCap 3544556354.0
- FreeCF/Share -0.2997
- PFCF -92.6827
- PE -83.3275
- Debt/Assets 0.0169
- DivYield 0
- ROE -0.2969
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ARQT | Goldman | -- | Neutral | -- | $18 | July 25, 2025 |
| Initiation | ARQT | H.C. Wainwright | -- | Buy | -- | $19 | Dec. 30, 2024 |
| Initiation | ARQT | Jefferies | -- | Buy | -- | $15 | Aug. 28, 2024 |
News
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.32 per share a year ago.
Read More
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) have performed compared to their sector so far this year.
Read More
Arcutis and Padagis Agree to Stay Patent Lawsuit
Published: April 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is pleased to announce that Padagis Israel Pharmaceuticals Ltd., Padagis US LLC, and Padagis LLC (Padagis) have requested a stay to the ongoing patent litigation between Padagis and the Company, and the Company has agreed to enter a joint stipulation to stay the case, which was filed in the U.S. District Court for the District of Delaware on April 2, 2025. After the Court enters the joint stipulation, all calendared dates and trial for the …
Read More
How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 25.9% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.
Read More
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Read More
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 48.4% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
Published: February 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topical treatments including topical steroids Second poster will highlight improvements in patient-related outcomes with ZORYVE® (roflumilast) foam 0.3% in psoriasis of the scalp and body WESTLAKE VILLAGE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will present two posters at the 2025 American Academy of Dermatology (AAD) annual meeting which will take place in Orlando, …
Read More
Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Arcutis Biotherapeutics is a strong buy due to ZORYVE's rapid sales growth and potential for positive earnings within 12 months. ZORYVE, a non-steroidal cream for psoriasis and dermatitis, saw Q4 sales of $69.4M, a 413% YoY increase, beating sales estimates by $10.8M. ZORYVE has maintained quarterly growth of >40% since Q1 2024. Remarkably only one additional quarter of such robust growth will bring sales to a pace needed to achieve profitability.
Read More
U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of October 13, 2025 Application supported by positive efficacy and safety data from pivotal Phase 3 trial, pivotal long-term extension study, and Phase 1 pharmacokinetic study If approved, ZORYVE cream 0.05% will be a new topical therapy option for approximately 1.8 million children aged 2 to 5 with atopic dermatitis (AD) in the United States WESTLAKE VILLAGE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced …
Read More
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2024 Earnings Call Transcript
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Neutral
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance & Investor Relations Frank Watanabe - President & Chief Executive Officer Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Vikram Purohit - Morgan Stanley Tyler Van Buren - TD Cowen Seamus Fernandez - Guggenheim Securities Serge Belanger - Needham & Co. Uy Ear - Mizuho Kambiz Yazdi - Jefferies Douglas Tsao - H.C. Wainwright Operator Good day and welcome to Arcutis Biotherapeutics 2024 …
Read More
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- WESTLAKE VILLAGE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) – Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2024, and provided a business update.
Read More
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
ZORYVE® (roflumilast) cream 0.05% improved atopic dermatitis (AD) across all primary and secondary efficacy endpoints, with significant improvement as early as Week 1 on multiple efficacy endpoints. 39.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in Eczema Area and Severity Index (EASI-75), a key secondary endpoint.
Read More
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
WESTLAKE VILLAGE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the TD Cowen 45th Annual Health Care Conference, taking place March 3-5, 2025.
Read More
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 51.6% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About Arcutis Biotherapeutics, Inc. (ARQT)
- IPO Date 2020-01-31
- Website https://www.arcutis.com
- Industry Biotechnology
- CEO Todd Franklin Watanabe
- Employees 342